Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.

ABSTRACT:

Background

Cladribine is an effective immunotherapy for people with multiple sclerosis (pwMS). Whilst most pwMS do not require re-treatment following standard dosing (two treatment courses), disease activity re-emerges in others. The characteristics of pwMS developing re-emerging disease activity remain incompletely understood.

Objectives

To explore whether clinical and/or paraclinical baseline characteristics, including the degree of lymphocyte reduction, drug dose and lesions on magnetic resonance imaging (MRI) are associated with re-emerging disease activity.

Design

Service evaluation in pwMS undergoing subcutaneous cladribine (SClad) treatment.

Methods

Demographics, clinical, laboratory and MRI data of pwMS receiving two courses of SClad were extracted from

SUBMITTER: Allen-Philbey K 

PROVIDER: S-EPMC10638874 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature